EGFR and non-small cell lung carcinoma: The use of crystal dPCR to detect EGFR mutations in plasma cfDNA and corresponding CTCs from NSCLC patients before and after osimertinib treatment revealed complementary findings, but the results differed between CTC and ctDNA assessments [173].